Kesimpta and Hemiparesis - a phase IV clinical study of FDA data

Summary:

Hemiparesis is reported as a side effect among people who take Kesimpta (ofatumumab), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Vitamin D, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Hemiparesis when taking Kesimpta. It is created by eHealthMe based on reports of 36,581 people who have side effects when taking Kesimpta from the FDA, and is updated regularly.

What is Kesimpta?

Kesimpta has active ingredients of ofatumumab. eHealthMe is studying from 36,592 Kesimpta users. Check the latest studies of Kesimpta.

What is Hemiparesis?

Hemiparesis (weakness on one side of the body) is found to be associated with 1,251 drugs and 1,445 conditions by eHealthMe. Check the latest studies of Hemiparesis.

On Aug, 09, 2026

36,581 people reported to have side effects when taking Kesimpta.
Among them, 178 people (0.49%) have Hemiparesis.

Among these 178 people:

* Approximation only. Some reports may have incomplete information.

Do you take Kesimpta and have Hemiparesis?

- Check whether Hemiparesis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kesimpta:

Kesimpta (36,592 reports)

Hemiparesis treatments and more:

Hemiparesis (23,885 reports)

How severe was Hemiparesis and when was it recovered:

Hemiparesis in Kesimpta

Expand to all the drugs that have ingredients of ofatumumab:

Hemiparesis and drugs with ingredients of ofatumumab

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Kesimpta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hemiparesis:

Hemiparesis (1,251 drugs)

Browse all the conditions that are associated with Hemiparesis:

Hemiparesis (1,445 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ofatumumab (the active ingredients of Kesimpta) and Kesimpta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.